Lynnette Averill

Lynnette Averill is an Assistant Professor and Clinical Research Psychologist at the National Center for PTSD – Clinical Neurosciences Division and Yale School of Medicine, Department of Psychiatry. She is currently engaged in clinical trials evaluating functional and anatomical connectivity patterns in Veterans with PTSD, Suicidal Ideation, and Suicide Attempts, and is planning a collaboration to examine the anti-suicidal effects of MDMA on suicidality in PTSD.

CV

Dr. Lynnette Averill completed her Ph.D. in the field of counseling psychology and went on to acquire expertise in translational clinical neuroscience with an emphasis on pharmacoimaging trials of glutamate-based drugs (namely ketamine) evaluating behavioral and neural alterations in suicidality, trauma, and stress-related psychiatric disorders. I am also interested in the role of disrupted sleep in suicidality and PTSD and opioid misuse as it relates to suicidality and self-medicating psychiatric symptoms, and the need for effective risk screening and stratification.

Notable Research Papers

• Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin (Averill, et al., 2020)
• The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects (Averill, et al., 2017)
• Ketamine treatment and global brain connectivity in major depression (Averill, et al., 2017)

Find more on Google Scholar or PubMed

In our database you will also find her as an author on many more papers.

Media

• Lynette Averill, PhD, on moving from counseling psychology to neuroscience, getting a Fulbright, and ketamine research (Research Matters podcast, 2020)
• Clinical trials press on for conditions other than COVID-19. Will the pandemic’s effects sneak into their data? (Science, 2020)